Patents Assigned to Receptopharm, Inc.
  • Patent number: 8034777
    Abstract: The invention comprises a composition of matter and method of its use for the treatment of multiple sclerosis in humans. The composition is a modified anticholinergic alpha-neurotoxin. Alpha-neurotoxin solution, such as cobratoxin, is filter sterilized to remove bacteria. It is modified using H2O2. Any suitable preservative for parenteral administration can be employed such as methyl paraben, benzalkonium chloride or metacreosol. It is preferred that the composition is administered every other day or daily. The composition may be administered orally, subcutaneously, intramuscularly or intravenously. Parenterally, either subcutaneous or intramuscular injection is preferred.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: October 11, 2011
    Assignee: Receptopharm, Inc.
    Inventors: Paul F. Reid, Laurence N. Raymond
  • Patent number: 7902152
    Abstract: A composition of matter for an analgesia and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to blocking of the action of acetylcholine at nicotinic acetylcholine receptors.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: March 8, 2011
    Assignee: Receptopharm, Inc.
    Inventors: Paul F. Reid, Zheng Hong Qin
  • Patent number: 7758894
    Abstract: Detoxified cobra venom and its constituent neurotoxins have been reported to have potent antiviral activity. Others have reported that snake venoms were generally immune stimulants. Recent research has revealed more specific details on the effects of detoxified venoms and isolated alpha-neurotoxins on cells of the immune system. Exposure of the immune cells to these detoxified proteins yields a strong response in the innate immune reaction that represents the immune systems initial response to infectious agents. Of particular relevance is the marked increase in the expression of genes associated with the production of gamma interferon, a potent antiviral agent and regulator of the immune response. The ability to induce this strong innate response has significant application to those with weakened immune systems where their ability to fight infection has been compromised.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: July 20, 2010
    Assignee: Receptopharm, Inc.
    Inventors: Paul F. Reid, Laurence N. Raymond